WGU D116 Advanced Pharmacology OA Exam Prep
Document | 2026/2027 Edition | 200 Verified Questions - 172
Questions with Answers
WGU D116 Advanced Pharmacology OA 2026-172 QUESTIONS AND ANSWERS ALREADY GRADED A+.
100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document is meticulously designed for nursing students enrolled
in WGU D116 Advanced Pharmacology. It features 200 verified practice questions and answers, each
accompanied by detailed rationales and explanations. The content is aligned with the latest 2026/2027
academic guidelines and reflects the most current pharmacological principles and clinical applications.
This guide is an essential resource for mastering the material and achieving a high score on the
Objective Assessment.
Key Features:
Pharmacokinetics and pharmacodynamics
Drug classifications and mechanisms of action
Adverse effects and drug interactions
Clinical application and patient education
Special populations considerations
Evidence-based prescribing and safety
Updates for 2026:
- Revised to align with 2026/2027 WGU D116 curriculum updates
- Incorporated new FDA-approved medications and withdrawn drugs
- Enhanced rationales with evidence-based guidelines and clinical pearls
- Added updated safety alerts and black box warnings
- Expanded coverage of pharmacogenomics and personalized medicine
Abstract:
This exam preparation guide for WGU D116 Advanced Pharmacology provides a rigorous and comprehensive
review of advanced pharmacological concepts essential for nursing practice. The 200 verified questions are
strategically distributed across core content areas, including pharmacokinetics, pharmacodynamics, drug
classifications, and therapeutic applications. Each question is paired with a detailed answer explanation that
clarifies the correct choice and analyzes distractors, reinforcing critical thinking and clinical reasoning. The
content is updated to reflect the latest 2026/2027 academic standards and incorporates current evidence-based
practice guidelines. Special emphasis is placed on safe prescribing, monitoring, patient education, and
management of adverse effects across diverse patient populations. This guide is an indispensable tool for students
seeking to excel in the Objective Assessment and to enhance their competence in advanced pharmacology.
Keywords:
Advanced Pharmacology, WGU D116, Objective Assessment, Pharmacokinetics, Pharmacodynamics, Drug
Interactions, Nursing Exam Prep, 2026/2027
Answer Format:
Each question is followed by the correct answer and a comprehensive rationale explaining why it is correct.
Additionally, each incorrect option (distractor) is analyzed to clarify why it is not the best choice, enhancing
understanding of pharmacological principles and clinical decision-making.
Compliance Checklist:
Page 1
, Aligned with WGU D116 course objectives and competencies
Updated to reflect 2026/2027 academic guidelines and current practice standards
Includes 200 verified questions with accurate answers and evidence-based rationales
Covers all major content areas as specified in the exam blueprint
Designed to promote critical thinking and clinical application
Suitable for self-assessment and comprehensive review
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-30 Absorption, Distribution, Metabolism, 15%
Pharmacodynamics Excretion, Receptor Theory, Dose-Response
Autonomic and Cardiovascular 31-60 Adrenergic Agonists/Antagonists, 15%
Pharmacology Cholinergic Agents, Antihypertensives,
Antiarrhythmics, Anticoagulants
Neuropharmacology and 61-90 Antidepressants, Antipsychotics, 15%
Psychopharmacology Antiepileptics, Anxiolytics, Opioid
Analgesics
Endocrine and Metabolic 91-120 Insulin and Oral Hypoglycemics, Thyroid 15%
Pharmacology Medications, Corticosteroids, Bone
Metabolism Agents
Antimicrobial and 121-150 Antibiotics, Antivirals, Antifungals, 15%
Anti-inflammatory NSAIDs, DMARDs
Pharmacology
Special Populations and Safety 151-180 Pediatric, Geriatric, Pregnancy/Lactation, 15%
Renal/Hepatic Impairment, Drug
Interactions
Clinical Application and Patient 181-200 Prescribing Principles, Monitoring 10%
Education Parameters, Adverse Effects Management,
Patient Counseling
Page 2
,Q1. A patient with treatment-resistant major depressive disorder has failed two
adequate trials of SSRIs. Which pharmacologic strategy is most appropriate as the
next evidence-based step?
A. Augment with a second-generation antipsychotic such as aripiprazole
B. Switch to a monoamine oxidase inhibitor (MAOI) such as phenelzine
C. Add a tricyclic antidepressant such as amitriptyline
D. Increase the SSRI dose to the maximum tolerated level
Correct Answer: A. Augment with a second-generation antipsychotic such as
aripiprazole
Rationale: For treatment-resistant depression, evidence supports augmentation with
second-generation antipsychotics (e.g., aripiprazole, quetiapine) as first-line adjunctive
therapy. MAOIs are reserved for atypical depression or after multiple failed trials due to
safety concerns. Switching to a TCA or simply increasing SSRI dose are less effective or
not the next recommended step.
Why Wrong:
B - MAOIs are not first-line augmentation due to dietary restrictions and risk of
hypertensive crisis.
C - TCAs are not preferred for augmentation due to their side effect profile and
limited evidence.
D - Maximizing SSRI dose is reasonable but not the next step after two failed
adequate trials; augmentation is preferred.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 14
Q2. A patient on warfarin for atrial fibrillation develops a pulmonary embolism.
Which anticoagulant adjustment is most appropriate?
A. Switch to a direct oral anticoagulant (DOAC) such as apixaban
B. Increase warfarin dose to achieve INR 3-4
C. Add aspirin 81 mg daily to warfarin
D. Discontinue warfarin and start therapeutic enoxaparin alone
Correct Answer: A. Switch to a direct oral anticoagulant (DOAC) such as apixaban
Rationale: In patients with atrial fibrillation who develop a venous thromboembolism
while on warfarin, current guidelines recommend switching to a DOAC (e.g., apixaban,
rivaroxaban) for better efficacy and safety. Increasing INR target is not indicated for VTE
treatment. Adding aspirin increases bleeding risk without benefit. Enoxaparin alone is not
adequate long-term therapy without an oral anticoagulant.
Why Wrong:
B - Higher INR targets (3-4) are not recommended for VTE treatment and increase
bleeding risk.
C - Adding aspirin to warfarin increases bleeding without additional thromboembolic
Page 3
, protection.
D - Enoxaparin alone is not appropriate for long-term management; transition to an
oral agent is required.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 34
Q3. A patient with type 2 diabetes and chronic kidney disease (eGFR 35 mL/min)
needs an antihyperglycemic agent. Which medication is most appropriate?
A. Metformin
B. Empagliflozin
C. Glyburide
D. Pioglitazone
Correct Answer: B. Empagliflozin
Rationale: Empagliflozin is a sodium-glucose cotransporter-2 inhibitor that is preferred in
patients with diabetic kidney disease due to cardiorenal benefits and can be used down to
eGFR 20 mL/min. Metformin is contraindicated when eGFR <30 mL/min. Glyburide is
poorly tolerated in renal impairment due to hypoglycemia risk. Pioglitazone is not
preferred in heart failure and has limited renal benefit.
Why Wrong:
A - Metformin is contraindicated at eGFR <30 mL/min due to lactic acidosis risk.
C - Glyburide has active metabolites that accumulate in renal impairment, increasing
hypoglycemia risk.
D - Pioglitazone is not preferred due to fluid retention and lacks renal-specific
benefits.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 45
Q4. A patient prescribed digoxin for heart failure is also started on amiodarone.
What is the most important monitoring parameter?
A. Serum digoxin concentration and signs of toxicity
B. QT interval on ECG
C. Serum potassium levels
D. Liver function tests
Correct Answer: A. Serum digoxin concentration and signs of toxicity
Rationale: Amiodarone is a potent inhibitor of P-glycoprotein, which decreases renal and
biliary clearance of digoxin, leading to increased digoxin levels and toxicity. Therefore,
monitoring digoxin concentrations and signs of toxicity is critical. QT interval is relevant
for amiodarone alone but not the primary interaction with digoxin. Potassium affects
digoxin toxicity but is not the primary monitoring parameter for this interaction.
Why Wrong:
B - QT interval is important for amiodarone but not the primary interaction with
Page 4
Document | 2026/2027 Edition | 200 Verified Questions - 172
Questions with Answers
WGU D116 Advanced Pharmacology OA 2026-172 QUESTIONS AND ANSWERS ALREADY GRADED A+.
100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document is meticulously designed for nursing students enrolled
in WGU D116 Advanced Pharmacology. It features 200 verified practice questions and answers, each
accompanied by detailed rationales and explanations. The content is aligned with the latest 2026/2027
academic guidelines and reflects the most current pharmacological principles and clinical applications.
This guide is an essential resource for mastering the material and achieving a high score on the
Objective Assessment.
Key Features:
Pharmacokinetics and pharmacodynamics
Drug classifications and mechanisms of action
Adverse effects and drug interactions
Clinical application and patient education
Special populations considerations
Evidence-based prescribing and safety
Updates for 2026:
- Revised to align with 2026/2027 WGU D116 curriculum updates
- Incorporated new FDA-approved medications and withdrawn drugs
- Enhanced rationales with evidence-based guidelines and clinical pearls
- Added updated safety alerts and black box warnings
- Expanded coverage of pharmacogenomics and personalized medicine
Abstract:
This exam preparation guide for WGU D116 Advanced Pharmacology provides a rigorous and comprehensive
review of advanced pharmacological concepts essential for nursing practice. The 200 verified questions are
strategically distributed across core content areas, including pharmacokinetics, pharmacodynamics, drug
classifications, and therapeutic applications. Each question is paired with a detailed answer explanation that
clarifies the correct choice and analyzes distractors, reinforcing critical thinking and clinical reasoning. The
content is updated to reflect the latest 2026/2027 academic standards and incorporates current evidence-based
practice guidelines. Special emphasis is placed on safe prescribing, monitoring, patient education, and
management of adverse effects across diverse patient populations. This guide is an indispensable tool for students
seeking to excel in the Objective Assessment and to enhance their competence in advanced pharmacology.
Keywords:
Advanced Pharmacology, WGU D116, Objective Assessment, Pharmacokinetics, Pharmacodynamics, Drug
Interactions, Nursing Exam Prep, 2026/2027
Answer Format:
Each question is followed by the correct answer and a comprehensive rationale explaining why it is correct.
Additionally, each incorrect option (distractor) is analyzed to clarify why it is not the best choice, enhancing
understanding of pharmacological principles and clinical decision-making.
Compliance Checklist:
Page 1
, Aligned with WGU D116 course objectives and competencies
Updated to reflect 2026/2027 academic guidelines and current practice standards
Includes 200 verified questions with accurate answers and evidence-based rationales
Covers all major content areas as specified in the exam blueprint
Designed to promote critical thinking and clinical application
Suitable for self-assessment and comprehensive review
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-30 Absorption, Distribution, Metabolism, 15%
Pharmacodynamics Excretion, Receptor Theory, Dose-Response
Autonomic and Cardiovascular 31-60 Adrenergic Agonists/Antagonists, 15%
Pharmacology Cholinergic Agents, Antihypertensives,
Antiarrhythmics, Anticoagulants
Neuropharmacology and 61-90 Antidepressants, Antipsychotics, 15%
Psychopharmacology Antiepileptics, Anxiolytics, Opioid
Analgesics
Endocrine and Metabolic 91-120 Insulin and Oral Hypoglycemics, Thyroid 15%
Pharmacology Medications, Corticosteroids, Bone
Metabolism Agents
Antimicrobial and 121-150 Antibiotics, Antivirals, Antifungals, 15%
Anti-inflammatory NSAIDs, DMARDs
Pharmacology
Special Populations and Safety 151-180 Pediatric, Geriatric, Pregnancy/Lactation, 15%
Renal/Hepatic Impairment, Drug
Interactions
Clinical Application and Patient 181-200 Prescribing Principles, Monitoring 10%
Education Parameters, Adverse Effects Management,
Patient Counseling
Page 2
,Q1. A patient with treatment-resistant major depressive disorder has failed two
adequate trials of SSRIs. Which pharmacologic strategy is most appropriate as the
next evidence-based step?
A. Augment with a second-generation antipsychotic such as aripiprazole
B. Switch to a monoamine oxidase inhibitor (MAOI) such as phenelzine
C. Add a tricyclic antidepressant such as amitriptyline
D. Increase the SSRI dose to the maximum tolerated level
Correct Answer: A. Augment with a second-generation antipsychotic such as
aripiprazole
Rationale: For treatment-resistant depression, evidence supports augmentation with
second-generation antipsychotics (e.g., aripiprazole, quetiapine) as first-line adjunctive
therapy. MAOIs are reserved for atypical depression or after multiple failed trials due to
safety concerns. Switching to a TCA or simply increasing SSRI dose are less effective or
not the next recommended step.
Why Wrong:
B - MAOIs are not first-line augmentation due to dietary restrictions and risk of
hypertensive crisis.
C - TCAs are not preferred for augmentation due to their side effect profile and
limited evidence.
D - Maximizing SSRI dose is reasonable but not the next step after two failed
adequate trials; augmentation is preferred.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 14
Q2. A patient on warfarin for atrial fibrillation develops a pulmonary embolism.
Which anticoagulant adjustment is most appropriate?
A. Switch to a direct oral anticoagulant (DOAC) such as apixaban
B. Increase warfarin dose to achieve INR 3-4
C. Add aspirin 81 mg daily to warfarin
D. Discontinue warfarin and start therapeutic enoxaparin alone
Correct Answer: A. Switch to a direct oral anticoagulant (DOAC) such as apixaban
Rationale: In patients with atrial fibrillation who develop a venous thromboembolism
while on warfarin, current guidelines recommend switching to a DOAC (e.g., apixaban,
rivaroxaban) for better efficacy and safety. Increasing INR target is not indicated for VTE
treatment. Adding aspirin increases bleeding risk without benefit. Enoxaparin alone is not
adequate long-term therapy without an oral anticoagulant.
Why Wrong:
B - Higher INR targets (3-4) are not recommended for VTE treatment and increase
bleeding risk.
C - Adding aspirin to warfarin increases bleeding without additional thromboembolic
Page 3
, protection.
D - Enoxaparin alone is not appropriate for long-term management; transition to an
oral agent is required.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 34
Q3. A patient with type 2 diabetes and chronic kidney disease (eGFR 35 mL/min)
needs an antihyperglycemic agent. Which medication is most appropriate?
A. Metformin
B. Empagliflozin
C. Glyburide
D. Pioglitazone
Correct Answer: B. Empagliflozin
Rationale: Empagliflozin is a sodium-glucose cotransporter-2 inhibitor that is preferred in
patients with diabetic kidney disease due to cardiorenal benefits and can be used down to
eGFR 20 mL/min. Metformin is contraindicated when eGFR <30 mL/min. Glyburide is
poorly tolerated in renal impairment due to hypoglycemia risk. Pioglitazone is not
preferred in heart failure and has limited renal benefit.
Why Wrong:
A - Metformin is contraindicated at eGFR <30 mL/min due to lactic acidosis risk.
C - Glyburide has active metabolites that accumulate in renal impairment, increasing
hypoglycemia risk.
D - Pioglitazone is not preferred due to fluid retention and lacks renal-specific
benefits.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 45
Q4. A patient prescribed digoxin for heart failure is also started on amiodarone.
What is the most important monitoring parameter?
A. Serum digoxin concentration and signs of toxicity
B. QT interval on ECG
C. Serum potassium levels
D. Liver function tests
Correct Answer: A. Serum digoxin concentration and signs of toxicity
Rationale: Amiodarone is a potent inhibitor of P-glycoprotein, which decreases renal and
biliary clearance of digoxin, leading to increased digoxin levels and toxicity. Therefore,
monitoring digoxin concentrations and signs of toxicity is critical. QT interval is relevant
for amiodarone alone but not the primary interaction with digoxin. Potassium affects
digoxin toxicity but is not the primary monitoring parameter for this interaction.
Why Wrong:
B - QT interval is important for amiodarone but not the primary interaction with
Page 4
